O. Wang

Gatekeeping procedures in dose–response clinical trials based on the Dunnett test

A. Dmitrienko, W. Offen, O. Wang, 2006, Pharmaceutical statistics.

Gatekeeping tests in dose-response clinical trials Alex Dmitrienko ( Eli Lilly )

W. Offen, O. Wang, D. Xiao, 2008 .

Statistical Power to Detect Cardiovascular Signals in First-in-Human Trials: Is It Really Small?

O. Wang, Michael D Hale, Jing Huang, 2013 .

Preclinical Evaluation of AMG 337, a Highly Selective Small Molecule MET Inhibitor, in Hepatocellular Carcinoma

Liaoyuan A. Hu, O. Wang, K. Rex, 2015, Molecular Cancer Therapeutics.

Clinical trials in "emerging markets": regulatory considerations and other factors.

O. Wang, R. Singh, 2013, Contemporary clinical trials.

Evaluation of cinacalcet HCl treatment after kidney transplantation.

O. Wang, O. Pankewycz, S. Katznelson, 2010, Transplantation proceedings.

Evolving statistical methods to facilitate evaluation of the causal association between erythropoiesis-stimulating agent dose and mortality in nonexperimental research: strengths and limitations.

K. Rothman, M. Joffe, H. Feldman, 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Exploring relative mortality and epoetin alfa dose among hemodialysis patients.

Kenneth J Rothman, Patrick Heagerty, Ouhong Wang, 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Relationship between epoetin alfa dose and mortality: findings from a marginal structural model.

K. Rothman, O. Wang, A. Collins, 2010, Clinical journal of the American Society of Nephrology : CJASN.

A TWO-STAGE DOSE SELECTION STRATEGY IN PHASE I TRIALS WITH WIDE DOSE RANGES

O. Wang, D. Faries, O. Wang, 2000, Journal of biopharmaceutical statistics.

Prevalence and Outcomes of Familial Hypercholesterolemia Patients in a Chinese Myocardial Infarction Cohort

O. Wang, Xi Li, Wenjin Li, 2017 .